Core Points - The company held its 2024 annual shareholders' meeting on June 6, 2025, with a shareholder attendance rate of 51.11% [1] - The cash dividend proposal received overwhelming support, with 99.91% approval from shareholders holding more than 5% of the shares [1] Summary by Categories Profit Distribution - The profit distribution plan for 2024 was approved with a support rate of 97.9% from minority investors, and 98.39% from shareholders with a market value below 500,000 [2] Financing Guarantees - The proposal for credit financing and providing guarantees for subsidiaries was approved with a 97.66% approval rate, although there was significant disagreement among minority investors, with only 44.38% in favor [2] Audit Reappointment - The reappointment of Deloitte Touche Tohmatsu as the auditing firm for 2025 was approved with a 99.74% support rate [2] Key Data - A total of 935 million shares were voted, representing 51.11% of the company's total share capital [3] Non-Operating Fund Usage - The special report on non-operating fund usage was approved with a 99.87% support rate [4] Subsidiary Loan Guarantees - The loan guarantee proposal for the subsidiary Jinguang Electric was supported by 99.83% of the votes [5] Compliance and Legality - The meeting procedures complied with the Company Law and the company's articles of association, presided over by director Lin Nanqi, with all board members and supervisors present [6] Impact - The resolutions clarified the company's financial distribution for 2024 and the financing guarantee framework for 2025, enhancing risk control for subsidiaries and maintaining audit stability, signaling robust operations to investors. Minority investors significantly benefited from the dividend plan but showed low participation in the financing guarantee matters [7]
健康元药业集团2024年年度股东大会通过多项议案 现金分红方案获高票支持